From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer
Chemical Biology & Drug Design · 2026-06 · 107 (6)
DOI: 10.1111/cbdd.70320 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 28.05.2026. Verfasst von Sandra Ferreira und 11 weiteren Autor:innen. Beteiligte Einrichtung: CBIOS, Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal. Hauptthemen laut MEDLINE: Amino Acid Oxidoreductases, Antineoplastic Agents, Thiazolidines, Enzyme Inhibitors. Die Arbeit nennt 60 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia, Universidade Lusófona/ILIND, National Research Foundation of Ukraine.
Abstract (Originalsprache)
Lysyl Oxidases (LOXs) catalyse elastin and collagen cross‐linking in the extracellular matrix and have been implicated in cancer cell progression and metastases, particularly in breast cancer. In this study, we sought small‐molecule inhibitors of LOXL2 using a library of 4‐thiazolidones supported by molecular docking. Five candidates were prioritised, with Les 5740 displaying the highest LOXL2 inhibitory activity (IC 50 of 27 μM). Although Les 5740 showed low cytotoxicity in various cancer and normal‐like cell lines, the triple‐negative breast cancer (TNBC) cell line MDA‐MB‐231 showed increased susceptibility to this molecule. Les 5740 did not induce DNA damage in mammary cells. At 30 μM, it increased TNBC cells' necrosis. The impact of a non‐toxic concentration of Les 5740 (5 μM) on TNBC cell motility was evaluated. Les 5740 reduced 2D chemoinvasion and altered cell morphology. These findings are consistent with a potential reduction in extracellular matrix stiffness as a consequence of LOXL2 inhibition. Les 5740 mildly inhibited tubulin polymerisation, supporting a multi‐target profile. Overall, Les 5740 should be viewed as a starting scaffold with LOXL2 inhibitory activity and broader cellular effects, motivating optimisation toward more potent and selective LOXL2 inhibitors for breast cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CBIOS, Universidade Lusófona's Research Center for Biosciences & Health Technologies, Lisbon, Portugal.
- Dpto. de Ciencias Biomédicas (Farmacología), Universidad de Alcala, Alcalá de Henares, Madrid, España.
- Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
- Molecular Design Center, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine.
- Department of Organic Chemistry, Medical University of Lublin, Lublin, Poland.
- Department of Biotechnology and Cell Biology, University of Information Technology and Management in Rzeszow, Rzeszow, Poland.
ORCID-Profile: Roman Lesyk, Daniel J V A Dos Santos, João G Costa
Förderung
- Fundação para a Ciência e a Tecnologia
- Universidade Lusófona/ILIND
- National Research Foundation of Ukraine
- Universidade Lusófona de Humanidades e Tecnologias
Zitieren
APA
Ferreira, S., Santos, B., Tavares, M., Holota, S., Khylyuk, D., Lesyk, R., Finyuk, N., Dos Santos, D. J. V. A., Díaz-Lanza, A. M., Costa, J. G., Saraiva, N., & Fernandes, A. S. (2026). From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer. Chemical Biology & Drug Design, 107(6). https://doi.org/10.1111/cbdd.70320
Vancouver
Ferreira S, Santos B, Tavares M, Holota S, Khylyuk D, Lesyk R, et al. From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer. Chemical Biology & Drug Design. 2026;107(6). doi:10.1111/cbdd.70320
BibTeX
@article{Ferreira2026,
author = {Ferreira, Sandra and Santos, Beatriz and Tavares, Matilde and Holota, Serhii and Khylyuk, Dmytro and Lesyk, Roman and Finyuk, Natalia and Dos Santos, Daniel J V A and Díaz-Lanza, Ana M and Costa, João G and Saraiva, Nuno and Fernandes, Ana S},
title = {From Virtual Screening to Cell Phenotype: 4‐Thiazolidone Scaffolds Targeting LOXL2 in Breast Cancer},
journal = {Chemical Biology & Drug Design},
year = {2026},
volume = {107},
number = {6},
doi = {10.1111/cbdd.70320}
}
EUVIMED